Patent 9561276 was granted and assigned to DUSA Pharmaceuticals on February, 2017 by the United States Patent and Trademark Office.
This application is directed to a method of treating onychomycosis by applying a phototherapeutic agent to a nail structure, waiting for a period of at least three days, and exposing the nail to light that causes an activation reaction. The phototherapeutic agent may be amino levulinic acid, alkylated derivatives of ALA, and their pharmaceutically acceptable salts.